bluuebunny/crossref_metadata_2025_split huggingface dataset:
Defining women’s incomes: household disruptions and gendered resolutions
Authors: Clingan Lauren 
Published: July 2024

Abstract
Women increasingly work for pay, disrupting cultural expectations and relational dynamics tied to men’s breadwinning. Scholars have examined how women’s incomes impact measures of domestic gender inequality, yet there is limited research on the mechanisms underlying that relationship, including how households define and spend women’s wages. Adopting economic sociology’s relational work approach, this study shows how tandem processes, relational accounting of feminine consumption and relational obfuscation of women’s earnings, shape the meaning of women’s work—processes that extend beyond marital dyads to involve siblings, children, and parents. Drawing from interviews with sixty-four Emirati women and men, I show how households leverage contradictory feminine consumption norms to designate women’s wages as communal resources, while at the same time, they conceal women’s financial contributions and disproportionately recognize men’s breadwinning. I call these relational adaptations to the breakdown of patriarchal bargains predicated on men’s provision gendered resolutions, because they illustrate processes through which women’s wages may paradoxically uphold unequal gendered arrangements. This study offers a framework to understand shifting gender relations during periods of economic change.
Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis
Authors: Sîrbulescu Ruxandra F. , Nicholson Katharine , Kawai Kento , Hilton Orla M. , Sobell Don , Jin Gina , Verrill David E. , Dwyer Liam J. , Xiong Yueyue , Bachanová Petra , Kim Spencer E. , Gallup Shannon , Gelevski Dario , Daley Heather , Hernandez Rodriguez Diego E. , Negre Hélène , Sturtevant Olive , Nikiforow Sarah , Ritz Jerome , Chen Yi‐Bin , Reeves Patrick M. , Sluder Ann E. , Berry James D. , Sadri‐Vakili Ghazaleh , Cudkowicz Merit , Poznansky Mark C. 
Published: July 2024

AbstractAmyotrophic lateral sclerosis (ALS) is an orphan neurodegenerative disease. Immune system dysregulation plays an essential role in ALS onset and progression. Our preclinical studies have shown that the administration of exogenous allogeneic B cells improves outcomes in murine models of skin and brain injury through a process termed pligodraxis, in which B cells adopt an immunoregulatory and neuroprotective phenotype in an injured environment. Here, we investigated the effects of B‐cell therapy in the SOD1G93A mouse preclinical model of ALS and in a person living with ALS. Purified splenic mature naïve B cells from haploidentical donor mice were administered intravenously in SOD1G93A mice for a total of 10 weekly doses. For the clinical study in a person with advanced ALS, IgA gammopathy of unclear significance, and B lymphopenia, CD19+ B cells were positively selected from a healthy haploidentical donor and infused intravenously twice, at a 60‐day interval. Repeated intravenous B‐cell administration was safe and significantly delayed disease onset, extended survival, reduced cellular apoptosis, and decreased astrogliosis in SOD1G93A mice. Repeated B‐cell infusion in a person with ALS was safe and did not appear to generate a clinically evident inflammatory response. An improvement of 5 points on the ALSFRS‐R scale was observed after the first infusion. Levels of inflammatory markers showed persistent reduction post‐infusion. This represents a first demonstration of the efficacy of haploidentical B‐cell infusion in the SOD1G93A mouse and the safety and feasibility of using purified haploidentical B lymphocytes as a cell‐based therapeutic strategy for a person with ALS.
Comments and illustrations of the European Federation of Societies for Ultrasound in Medicine contrast-enhanced ultrasonography guidelines: multiparametric imaging and EUS-guided sampling in rare pancreatic tumors. Mesenchymal pancreatic tumors of intermediate biological behaviour
Authors: Möller Kathleen , Holz Tamara , Jenssen Christian , Braden Barbara , Hocke Michael , On Wei , Everett Simon M. , Dong Yi , Ge Nan , Sun Siyu , Gerber Michael , Faiss Siegbert , Schlag Christoph , Srivastava David , Dietrich Christoph F. 
Published: July 2024

ABSTRACT
The focus of the review is on mesenchymal pancreatic tumors with intermediate biological behavior and their imaging appearance. Similar to benign and malignant mesenchymal pancreatic tumors, these tumors are extremely rare. The diagnosis is often confirmed only by postoperative histology. The very limited data on abdominal ultrasound and EUS findings including contrast-enhanced techniques of these pancreatic lesions are summarized here.
RETINAL STRUCTURAL CHANGES AFTER CESSATION OF PENTOSAN POLYSULFATE SODIUM
Authors: Kalaw Fritz Gerald P. , Most Jesse , Kako Rasha Nabil , Sharma Paripoorna , Arias Juan D. , Chen Jimmy S. , Lin Andrew C. , Walker Evan , Bartsch Dirk-Uwe G. , Baxter Sally L. , Ferreyra Henry , Freeman William R. , Borooah Shyamanga 
Published: July 2024

Purpose:
To quantify baseline and longitudinal structural changes post-cessation in patients with pentosan polysulfate sodium retinopathy.

Methods:
This is a retrospective cohort study. Retinal thickness and volume of choroidal and hyperreflective retinal pigment epithelium excrescences were manually segmented from optical coherence tomography volume scans. Baseline measurements were compared against age-matched control subjects. Longitudinal measurements were performed on patients with follow-up data.

Results:
Twenty-four eyes of 13 patients were included. At baseline, the mean total retinal thickness was lower in the pentosan polysulfate sodium retinopathy cohort than in age- and sex-matched control subjects (269.1 µm vs. 290.2 µm, P = 0.006). The median (range) of follow-up was 18.6 (4.1–34.7) months, with the mean last follow-up of 35.2 months after cessation. During the follow-up period, the thickness of the retina decreased significantly by 11.3 µm (CI: 16.8, 5.8) (P < 0.001), with an annual mean decrease of 6.70 µm. However, the mean hyperreflective retinal pigment epithelium excrescence volume did not change significantly (P = 0.140) over the follow-up period.

Conclusion:
After pentosan polysulfate sodium discontinuation, although retinal pigment epithelium excrescence volume do not change significantly, there continues to be a progressive long-term thinning of the retina, which continues at a rate greater than that associated with normal aging. Consequently, long-term follow-up is suggested to monitor patients with pentosan polysulfate sodium retinopathy.
FIVE-YEAR CHANGES IN METAMORPHOPSIA AND THE ASSOCIATION OF OUTER RETINAL LAYERS AFTER VITRECTOMY FOR RHEGMATOGENOUS RETINAL DETACHMENT INVOLVING THE MACULA
Authors: Okuda Tetsuhiko , Higashide Tomomi , Sugiyama Kazuhisa 
Published: July 2024

Purpose:
To evaluate the 5-year changes in metamorphopsia and outer retinal morphology after vitrectomy for macula-off rhegmatogenous retinal detachment.

Methods:
The authors included 21 eyes from 21 patients with macula-off rhegmatogenous retinal detachment who underwent pars plana vitrectomy. Metamorphopsia was quantified using M-CHARTS. Using spectral-domain optical coherence tomography, the authors assessed the risk factors for metamorphopsia severity 5 years after surgery.

Results:
Metamorphopsia scores substantially improved from 1 month to 5 years postoperatively; however, they remained unchanged from 1 year to 5 years postoperatively. Overall, 11 patients (52.4%) had metamorphopsia 5 years postoperatively. The metamorphopsia scores in eyes with a continuous interdigitation zone and ellipsoid zone at 5 years were considerably lower than those in eyes with a disrupted interdigitation zone. Multiple regression analysis revealed that the metamorphopsia score at 5 years was markedly associated with the score at 1 month and continuous interdigitation zone.

Conclusion:
No statistically significant change was observed in metamorphopsia scores after 1 year postoperatively, and >50% of the patients had metamorphopsia at 5 years postoperatively. The improvement was associated with lower metamorphopsia scores at 1 month and continuous interdigitation zone at 5 years. Moreover, the study revealed that early metamorphopsia was a poor prognostic marker for long-term functional deficits.
SUPPLEMENTAL DEXTROSE IN THE INFUSION FLUID DURING DIABETIC VITRECTOMY
Authors: Schildroth Kathleen R. , Peterson Kyle D. , Altaweel Michael M. , Channa Roomasa , Chang Jonathan S. , Gottlieb Justin L. , Ip Michael S. , Nork T. Michael 
Published: July 2024

Purpose:
Historically, supplemental dextrose to infusion fluid has been used to reduce the need for intraoperative lensectomies to maintain visualization during diabetic vitrectomy. Valved, small-gauge vitrectomy has reduced surgical time and decreased intraoperative fluid flow. Assessment of supplemental dextrose in modern vitrectomy is presented in this study.

Methods:
A retrospective cohort study of diabetic patients undergoing vitrectomy was conducted. The dextrose group received supplemental dextrose in the infusion fluid, while the nondextrose group used a standard balanced salt solution (BSS Plus). Group assignment was per surgeons' typical practice patterns. Eyes with tractional retinal detachments were also evaluated as a subgroup.

Results:
Three hundred thirty phakic eyes were included. Supplemental dextrose was used in 199 eyes (60.3%). One unplanned lensectomy was performed in this series, in the nondextrose group, not statistically different from the dextrose group, with zero lensectomies (P = 0.4). Cataract survival curves overlapped for all eyes and for the tractional retinal detachment subgroup.

Conclusion:
In modern vitrectomy, unplanned lensectomy is rare. No difference was observed in the rate of intraoperative lensectomies or overall postoperative cataract course with or without dextrose supplementation to the infusion fluid. Standard solutions appear to be adequate for infusion, even for diabetics.
OPTICAL COHERENCE TOMOGRAPHY FEATURES ASSOCIATED WITH VITREOMACULAR TRACTION RELEASE AND MACULAR HOLE SIZE PROGRESSION FOLLOWING TREATMENT WITH OCRIPLASMIN
Authors: Johannigmann-Malek Navid , Iannetta Danilo , Zheng Yalin , Kaye Stephen B. , Groselli Sofia , Kirchmair Katharina , Dervenis Nikolaos , Issa Peter Charbel , Baumann Carmen 
Published: July 2024

Purpose:
To evaluate OCT features for vitreomacular traction (VMT) release and change in macular hole (MH) size after treatment with ocriplasmin.

Methods:
Patients who had undergone treatment with ocriplasmin for VMT with or without MH ≤400 µm were included. The main outcomes were VMT release and changes in minimum linear diameter MH size at 4 weeks in MHs that persisted. OCT features evaluated were central retinal thickness, vitreomacular adhesion length, posterior vitreous cortex (PVC) insertion angles 500 µm from the insertion points, and minimum linear diameter size.

Results:
Sixty patients were included: 37 had isolated VMT and 23 VMT with a MH. Four weeks after ocriplasmin injection, the overall VMT release rate was 66.7% (40/60); 64.9% (24/37) in eyes with isolated VMT and 69.6% (16/23) in eyes with MH. VMT release was associated with younger age (P = 0.02). Macular hole closure was achieved in 26.1% (6/23) and was associated with a smaller ratio of the temporal to the nasal PVC angle (P < 0.01). Of the 17 persistent MHs, 76.5% (13/17) increased in minimum linear diameter size from baseline 186 (±78) to 358 (±133) µm (P < 0.001). Progression in minimum linear diameter size showed a negative linear association with the size of the nasal PVC angle (R2 = 0.39, P = 0.002) and a positive linear association with the ratio of the temporal to nasal PVC angle (R2 = 0.39, P = 0.002).

Conclusion:
In patients with VMT-associated MHs, the risk of MH enlargement following ocriplasmin is negatively correlated with the nasal PVC angle size and is increased if the ratio of the temporal to nasal angle is >1.
Mpox Keratitis: A Case Report and Review
Authors: Croasdale Christopher R. , Weinlander Eric , Boyce Thomas G. 
Published: July 2024

Purpose:
Mpox is a rare infectious disease. Lack of knowledge among eye care professionals regarding mpox keratitis greatly reduces the likelihood of diagnosis and effective management. This report and review seek to increase the knowledge of mpox keratitis among eye care professionals.

Methods:
We report a patient with mpox keratitis who underwent successful penetrating keratoplasty, with 20 years of follow-up. A systematic literature search and review of cases of mpox keratitis from 1970 to 2024 was performed.

Results:
A total of 24 articles and 2 abstracts reporting 35 cases of mpox keratitis were identified. A frequency of 0.5% to 1.0% may be the lower range of mpox keratitis among symptomatic patients with a confirmed mpox diagnosis. Mpox keratitis occurred with and without systemic mpox. Initial misdiagnoses were common (40%). Polymerase chain reaction results aided clinical diagnosis. Corneal disease ranged from mild epitheliopathy to fulminant ulcerative keratitis. Outcomes ranged from 20/20 acuity to no light perception. In the absence of fulminant systemic disease, tecovirimat was associated with clinical improvement of mpox keratitis in almost all cases. Our case is the only known report of successful penetrating keratoplasty for mpox keratitis and the only case whereby monkeypox virus was cultured from the corneal surface.

Conclusions:
Mpox keratitis is rare but can result in severe vision loss and blindness. Systemic tecovirimat seems to be effective in treating mpox keratitis, although the low frequency of keratitis precludes clinical trials. Topical steroids may extend virus survival in the cornea. Polymerase chain reaction may help confirm mpox corneal involvement.
A systematic literature review on patient-reported outcome domains and measures in nonsurgical efficacy trials related to chronic pain associated with endometriosis: an urgent call to action
Authors: Rosenberger Daniela Constanze , Mennicken Emilia , Schmieg Iris , Medkour Terkia , Pechard Marie , Sachau Juliane , Fuchtmann Fabian , Birch Judy , Schnabel Kathrin , Vincent Katy , Baron Ralf , Bouhassira Didier , Pogatzki-Zahn Esther Miriam 
Published: July 2024

Abstract
Endometriosis, a common cause for chronic pelvic pain, significantly affects quality of life, fertility, and overall productivity of those affected. Therapeutic options remain limited, and collating evidence on treatment efficacy is complicated. One reason could be the heterogeneity of assessed outcomes in nonsurgical clinical trials, impeding meaningful result comparisons. This systematic literature review examines outcome domains and patient-reported outcome measures (PROMs) used in clinical trials. Through comprehensive search of Embase, MEDLINE, and CENTRAL up until July 2022, we screened 1286 records, of which 191 were included in our analyses. Methodological quality (GRADE criteria), information about publication, patient population, and intervention were assessed, and domains as well as PROMs were extracted and analyzed. In accordance with IMMPACT domain framework, the domain pain was assessed in almost all studies (98.4%), followed by adverse events (73.8%). By contrast, assessment of physical functioning (29.8%), improvement and satisfaction (14.1%), and emotional functioning (6.8%) occurred less frequently. Studies of a better methodological quality tended to use more different domains. Nevertheless, combinations of more than 2 domains were rare, failing to comprehensively capture the bio–psycho–social aspects of endometriosis-associated pain. The PROMs used showed an even broader heterogeneity across all studies. Our findings underscore the large heterogeneity of assessed domains and PROMs in clinical pain-related endometriosis trials. This highlights the urgent need for a standardized approach to both, assessed domains and high-quality PROMs ideally realized through development and implementation of a core outcome set, encompassing the most pivotal domains and PROMs for both, stakeholders and patients.
Stem cell therapy for COVID-19 treatment: an umbrella review
Authors: Tang Chaozhi , Dziedzic Arkadiusz , Khatib Mahalaqua Nazli , Alhumaid Saad , Thangavelu Lakshmi , Parameswari RP , Satapathy Prakasini , Zahiruddin Quazi Syed , Rustagi Sarvesh , Alanazi Maha Afri , Al-Thaqafy Majid S. , Hazazi Ali , Alotaibi Jawaher , Al Faraj Nehad J. , Al-Zaki Nisreen A. , Al Marshood Mona J. , Al Saffar Thuria Y. , Alsultan Khadija A. , Al-Ahmed Shamsah H. , Rabaan Ali A. 
Published: July 2024

Background:
COVID-19 has presented significant obstacles to healthcare. Stem cell therapy, particularly mesenchymal stem cells, has emerged as a potential treatment modality due to its immunomodulatory and regenerative properties. This umbrella review aims to synthesize current evidence from systematic reviews on the safety and efficacy of stem cell therapy in COVID-19 treatment.

Methods:
A thorough literature search was performed across Embase, PubMed, Cochrane, and Web of Science from December 2019 to February 2024. Systematic reviews focusing on the use of stem cell therapy for COVID-19 were included. Evidence was synthesized by meta-analysis using R software (V 4.3) for each outcome. The certainty of evidence was assessed using the GRADE approach.

Results:
A total of 24 systematic reviews were included. Stem cell therapy was associated with reduced mortality [risk ratio (RR) 0.72, 95% CI: 0.60–0.86]; shorter hospital stays (mean difference −4.00 days, 95% CI: −4.68 to −3.32), and decreased need for invasive ventilation (RR 0.521, 95% CI: 0.320–0.847). Symptom remission rates improved (RR 1.151, 95% CI: 0.998–1.330), and a reduction in C-reactive protein levels was noted (standardized mean difference −1.198, 95% CI: −2.591 to 0.195), albeit with high heterogeneity. For adverse events, no significant differences were found between stem cell therapy and standard care (RR 0.87, 95% CI: 0.607–1.265). The certainty of evidence ranged from low to moderate.

Conclusion:
Stem cell therapy demonstrates a potential benefit in treating COVID-19, particularly in reducing mortality and hospital stay duration. Despite these promising findings, the evidence is varied, and future large-scale randomized trials are essential to confirm the efficacy and optimize the therapeutic protocols for stem cell therapy in the management of the disease. The safety profile is encouraging, with no significant increase in adverse events, suggesting a viable avenue for treatment expansion.
Comparative efficacy and safety of olanzapine and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer’s disease: Systematic review and meta-analysis
Authors: Zhang Zhihua , Zhang Xijuan , Xu Lingyan 
Published: July 2024

Objectives:
Olanzapine and risperidone have emerged as the most widely used drugs as short-term prescription in the treatment of behavioral disturbances in dementia. The present systematic review and meta-analysis was hence performed to investigate the effectiveness and safety profile of olanzapine and risperidone in the treatment of behavioral and psychological symptoms of dementia (BPSD), aiming to provide updated suggestion for clinical physicians and caregivers.

Design:
Prospective controlled clinical studies were included, of which available data was extracted. Outcomes of BEHAVE-AD scores with the variation of grades, specific behaviors variables, as well as safety signals were pooled for the analysis by odds rates and weighted mean differences, respectively.

Data sources:
Medline, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and WanFang.

Eligibility criteria:
Prospective, controlled clinical studies, conducted to compare the effectiveness and safety profile of olanzapine and risperidone in the treatment of BPSD.

Data extraction and synthesis:
Interested data including baseline characteristics and necessary outcomes from the included studies were extracted independently by 2 investigators. BEHAVE-AD scale was adopted to assess the efficacy in the present study. All behaviors were evaluated at the time of the initiation of the treatment, as well as the completion of drugs courses. Adverse events were assessed with the criteria of Treatment Emergent Symptom Scale, or Coding Symbols for a Thesaurus of Adverse Reaction Terms dictionary. Weighted mean difference was used for the pooled analysis.

Results:
A total of 2427 participants were included in the present meta-analysis. Comparative OR on response rate, and remarkable response rate between olanzapine and risperidone was 0.65 (95% CI: 0.51–0.84; P = .0008), and 0.62 (95% CI: 0.50–0.78; P < .0001), respectively. There were statistical differences observed by olanzapine on the improvement of variables including delusions (WMD, −1.83, 95% CI, −3.20, −0.47), and nighttime behavior disturbances (WMD, −1.99, 95% CI, −3.60, −0.38) when compared to risperidone.

Conclusion:
Our results suggested that olanzapine might be statistically superior to risperidone on the reduction of BPSD of Alzheimer’s disease, especially in the relief of delusions and nighttime behavior disturbances. In addition, olanzapine was shown statistically lower risks of agitation, sleep disturbance, and extrapyramidal signs.
Analysis of traditional Chinese medicine syndrome elements and clinical symptoms in prediabetes: A systematic review
Authors: Lan Qin , Fang Jianhe , Yu Xinyu , Yang Caiyun , Lin Xingzhen , Wu Juan , Yan Lei , Jian Hui 
Published: July 2024

Background:
Prediabetes mellitus (PDM) and impaired glucose regulation precedes diabetes and serve as early warning signals. A 2018 Chinese epidemiological survey reported prediabetes at 25.5% prevalence and type 2 diabetes at 10.8%, respectively. Untreated carries one-third of the risk of diabetes progression. This study aimed to understand traditional Chinese medicine syndromes in PDM to guide clinical practice and diabetes prevention.

Methods:
We systematically searched the Chinese and English literature in PubMed, EMBASE, Sinomed, CNKI, VIP, Wanfang until March 31, 2023. We manually explored the Chinese prediabetes literature, trial registrations, and references, adhering to predefined criteria. The results were independently summarized by 2 researchers. Statistical analysis was performed using EXCEL, IBM SPSS 27.0, and IBM SPSS Modeler 18.0, with data mining techniques including association and cluster analysis.

Results:
Analysis of 23 clinical trials (8943 patients) identified phlegm dampness syndrome as predominant, with qi deficiency, dampness, and phlegm as the principal pathogenic elements. Spleen syndrome elements dominated, with a priori correlation analysis favoring spleen dampness. The prevalent PDM clinical symptoms include amnesia, mental fatigue, limb fatigue, dizziness, and lumbar discomfort.

Conclusion:
Prediabetes is strongly associated with spleen dampness, highlighting its role. Common traditional Chinese medicine syndrome elements include qi deficiency, phlegm, and dampness. Clinical diagnosis and treatment should prioritize syndrome differentiation and emphasize spleen-focused approaches. Although limited research exists on prediabetes syndromes, further exploration of PDM and spleen dampness is crucial.